Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-461-2315
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
How were Tyme Technologies' earnings last quarter?
Tyme Technologies Inc (NASDAQ:TYME) announced its earnings results on Thursday, August, 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History.
When is Tyme Technologies' next earnings date?
What price target have analysts set for TYME?
1 brokerages have issued 1-year price objectives for Tyme Technologies' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Tyme Technologies' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 769.6% from the stock's current price. View Analyst Price Targets for Tyme Technologies.
What is the consensus analysts' recommendation for Tyme Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (8/16/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030, assuming a 12% discount rate and 2% terminal growth rate." (8/12/2019)
Has Tyme Technologies been receiving favorable news coverage?
News headlines about TYME stock have been trending positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tyme Technologies earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Tyme Technologies.
Are investors shorting Tyme Technologies?
Tyme Technologies saw a drop in short interest in July. As of July 15th, there was short interest totalling 6,790,800 shares, a drop of 12.2% from the June 15th total of 7,734,000 shares. Based on an average daily volume of 826,800 shares, the days-to-cover ratio is currently 8.2 days. Approximately 16.8% of the shares of the stock are short sold. View Tyme Technologies' Current Options Chain.
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Viking Therapeutics (VKTX), Akebia Therapeutics (AKBA), Dermira (DERM), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Karuna Therapeutics (KRTX), Aptorum Group (APM), Syros Pharmaceuticals (SYRS), Milestone Pharmaceuticals (MIST), Sinovac Biotech (SVA), Advanz Pharma (CXRXF), Urogen Pharma (URGN), Crinetics Pharmaceuticals (CRNX), Organogenesis (ORGO) and CytomX Therapeutics (CTMX).
What other stocks do shareholders of Tyme Technologies own?
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
- Mr. Ben R. Taylor, Pres & CFO (Age 42)
- Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
- Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
- Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)
Who are Tyme Technologies' major shareholders?
Tyme Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.66%), Vanguard Group Inc. (2.00%), Northern Trust Corp (0.89%), Bank of New York Mellon Corp (0.27%), Paloma Partners Management Co (0.17%) and Wells Fargo & Company MN (0.13%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.
Which major investors are selling Tyme Technologies stock?
TYME stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, Charles Schwab Investment Management Inc. and Northern Trust Corp. View Insider Buying and Selling for Tyme Technologies.
Which major investors are buying Tyme Technologies stock?
TYME stock was acquired by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, Michele Ilene Korfin and Steve Hoffman. View Insider Buying and Selling for Tyme Technologies.
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $1.15.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $128.74 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.
What is Tyme Technologies' official website?
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
